Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
dural follicular non hodgkin lymphoma mimicking a chronic subdural hematoma a case report and literature review
Original title: “Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review.”
All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.
Original title: “Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study”
targeting cutaneous t cell lymphoma in non hodgkin lymphoma what s new for investigational agents
Original title: “Targeting Cutaneous T-cell lymphoma in non-hodgkin lymphoma: What's new for investigational agents?”
cladosporium cladosporioides fungemia in a patient with non hodgkin lymphoma an extremely rare case and review of the literature
Original title: “Cladosporium cladosporioides Fungemia in a Patient with Non-Hodgkin Lymphoma: An Extremely Rare Case and Review of the Literature.”
The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the ... The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology. Abbadessa: MDX2003 is currently administered via intravenous (IV) infusion, which would allow its use in the community clinic setting. Our plan is to develop this molecule for favorable dosing logistics, which will depend on data from the phase 1 trial. Our MSTAR molecules can be formulated for non-IV administration, and this can be addressed as the program progresses. AJMC: To confirm, this treatment would be for NHL conditions. Is there a particular disease state where it will be tested first? A phase 1 trial for MDX2003 will begin in early 2026, focusing on B-cell non-Hodgkin lymphomas. MDX2003 is administered via IV infusion, with potential for community clinic use and non-IV formulations in the future.SHOW MORE · The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. The phase 1 trial will be carried out in a range of B-cell non-Hodgkin lymphomas, which usually express CD19 and CD20. These lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphomas, indolent lymphomas, and Waldenström macroglobulinemia. More detailed information, with the inclusion and exclusion criteria, will be available on ClinicalTrial.gov once the study starts.
Original title: “What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells? | AJMC”